SEARCH:   Advanced

Blood, 1 January 2006, Vol. 107, No. 1, pp. 39-45. Prepublished online as a Blood First Edition Paper on September 8, 2005; DOI 10.1182/blood-2005-06-2305. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-06-2305v1 107/1/39    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mehta, P. A. Articles by Davies, S. M. Search for Related Content PubMed PubMed Citation Articles by Mehta, P. A. Articles by Davies, S. M. Related Collections Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report Parinda A. Mehta, Todd A. Alonzo, Robert B. Gerbing, James S. Elliott, Tiffany A. Wilke, Rebekah J. Kennedy, Julie A. Ross, John P. Perentesis, Beverly J. Lange, and Stella M. Davies From the Division of Hematology/Oncology, Department of Pediatrics, University of Cincinnati College of Medicine, and Cincinnati Children's Hospital Medical Center, Cincinnati, OH; the University of Southern California Keck School of Medicine; the Children's Oncology Group, Arcadia, CA; the Department of Pediatrics, University of Minnesota Cancer Center; and the Department of Pediatrics, The Children's Hospital of Philadelphia, PA. Genetic polymorphisms result in interindividual variation in DNA repair capacity and may, in part, account for susceptibility of a cell to genotoxic agents and to malignancy. Polymorphisms in XPD, a member of the nucleotide excision repair pathway, have been associated with development of treatment-related acute myeloid leukemia (AML) and with poor outcome of AML in elderly patients. We hypothesized that XPD Lys751Gln polymorphism may play a role in causation of AML in children and, as shown in adults, may affect the outcome of childhood AML therapy. Genotyping of 456 children treated for de novo AML was performed at XPD exon 23. Genotype frequencies in patients were compared with healthy control subject frequencies, and patient outcomes were analyzed according to genotype. Gene frequencies in AML patients and healthy controls were similar. There were no significant differences in overall survival (P = .82), event-free survival (P = .78), treatment-related mortality (P = .43), or relapse rate (RR) (P = .92) between patients with XPD751AA versus 751AC versus 751CC genotypes, in contrast to reports in adult AML. These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Wang, D. Chang, F.-l. Hu, H. Sui, B. Han, D.-d. li, and Y.-s. Zhao DNA Repair Gene XPD Polymorphisms and Cancer Risk: A Meta-analysis Based on 56 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 507 - 517. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials Blood, May 1, 2007; 109(9): 3936 - 3944. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020